Drug Profile
Haematopoietic stem cell gene therapy - Novartis/SyStemix
Alternative Names: CD34 anti-HIV gene therapy; CD34 anti-HIV therapy; CD34 gene therapy; Haematopoietic stem cell anti-HIV gene therapy; HSC anti-HIV gene therapy; HSC anti-HIV therapy; HSC gene therapyLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Duke University; Novartis; SyStemix
- Developer SyStemix
- Class Antivirals; Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 17 Sep 1999 No-Development-Reported for HIV infections treatment in USA (Unknown route)
- 01 May 1997 Phase-II clinical trials for HIV infections treatment in USA (Unknown route)